A study found that the long-acting monoclonal antibody nirsevimab, marketed as Beyfortus, reduced respiratory syncytial virus (RSV) associated hospital admissions in infants by 83%. The study included over 8000 infants who were randomly assigned to receive nirsevimab or standard care. The results showed that only 0.3% of infants in the nirsevimab group were admitted to the hospital for RSV, compared to 1.5% in the standard care group. The study, funded by Sanofi and AstraZeneca, took place in France, Germany, and the UK before and during the first RSV season in September and October 2022.
Source link
RSV jab reduced infant hospital admissions by 83%, study reports
